Real-life experience with fidaxomicin in Clostridioides difficile infection: a multicentre cohort study on 244 episodes

• Published in: Infection 2021-06, Vol.49 (3), p.475-482
• Main Authors: Escudero-Sánchez, Rosa, Valencia-Alijo, Angela, Cuéllar Tovar, Sandra, Merino-de Lucas, Esperanza, García Fernández, Sergio, Gutiérrez-Rojas, Ángela, Ramos-Martínez, Antonio, Salavert Lletí, Miguel, Castro Hernández, Iván, Giner, Livia, Cobo, Javier
• Format: Article
• Language: English
• Subjects: Antibiotics; Bacterial infections; Clinical trials; Clostridioides difficile; Cohort analysis; Family Medicine; General Practice; Health services; Infectious Diseases; Internal Medicine; Medicine; Medicine & Public Health; Original Paper; Patients; Risk analysis; Risk factors; Vancomycin
• ISSN: 0300-8126; 1439-0973
• DOI: 10.1007/s15010-020-01567-5

The high cost of fidaxomicin has restricted its use despite the benefit of a lower Clostridioides difficile infection (CDI) recurrence rate at 4 weeks of follow-up. This short follow-up represents the main limitation of pivotal clinical trials of fidaxomicin, and some recent studies question its benefits over vancomycin. Moreover, the main risk factors of recurrence after treatment with fidaxomicin remain unknown. We designed a multicentre retrospective cohort study among four Spanish hospitals to assess the efficacy of fidaxomicin in real life and to investigate risk factors of fidaxomicin failure at weeks 8 and 12. Two-hundred forty-four patients were included. Fidaxomicin was used in 96 patients (39.3%) for a first episode of CDI, in 95 patients (38.9%) for a second episode, and in 53 patients (21.7%) for a third or subsequent episode. Patients treated with fidaxomicin in a first episode were younger (59.9 years vs 73.5 years), but they had more severe episodes (52.1% vs. 32.4%). The recurrence rates for patients treated in the first episode were 6.5% and 9.7% at weeks 8 and 12, respectively. Recurrence rates increased for patients treated at second or ulterior episodes (16.3% and 26.4% at week 8, respectively). Age greater than or equal to 85 years and having had a previous episode of CDI were identified as recurrence risk factors at weeks 8 and 12. We conclude that the outcomes with fidaxomicin in real life are at least as good as those observed in clinical trials despite a more demanding evaluation. Be it 85 years of age or older, and the use after a first episode appears to be independent factors of CDI recurrence after treatment with fidaxomicin.